Peifen Fu
Overview
Explore the profile of Peifen Fu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1308
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen L, Li H, Zhang H, Yang H, Qian J, Li Z, et al.
JAMA
. 2024 Dec;
333(8):673-681.
PMID: 39671272
Importance: Preferred neoadjuvant strategies for early or locally advanced triple-negative breast cancer include a 4-drug chemotherapy regimen containing anthracyclines, cyclophosphamide, taxanes, and platinum. Blockade of the programmed death receptor 1/ligand-1...
2.
Jiang Z, Ouyang Q, Sun T, Zhang Q, Teng Y, Cui J, et al.
Future Oncol
. 2024 Dec;
21(4):421-429.
PMID: 39628303
No abstract available.
3.
Wang W, Wang X, Jiang Y, Guo Y, Fu P, He W, et al.
Br J Cancer
. 2024 Nov;
132(2):203-211.
PMID: 39609539
Background: Individuals with normal weight obesity (NWO) often escape the attention of healthcare providers who may assume that a normal body mass index (BMI) correlates with low health risks. However,...
4.
Wu L, Liu J, Geng Y, Fang J, Gao X, Lai J, et al.
Cancer Commun (Lond)
. 2024 Sep;
44(11):1311-1315.
PMID: 39297701
No abstract available.
5.
Xu C, Chen Z, Xia Y, Shi Y, Fu P, Chen Y, et al.
Cancer
. 2024 Aug;
130(S17):3054-3066.
PMID: 39092590
Antibody-drug conjugates (ADCs) have demonstrated effectiveness in treating various cancers, particularly exhibiting specificity in targeting human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Recent advancements in phase 3 clinical...
6.
Gao Y, Zhang M, Sun G, Ma L, Nie J, Yuan Z, et al.
Breast
. 2024 Jun;
76:103762.
PMID: 38924994
Background: Male breast cancer (MBC) is a rare disease. Although several large-scale studies have investigated MBC patients in other countries, the features of MBC patients in China have not been...
7.
Maimaitiaili A, Li Y, Chai N, Liu Z, Ling R, Zhao Y, et al.
Front Oncol
. 2024 May;
14:1326385.
PMID: 38800388
Purpose: This study aimed to investigate the factors associated with pathologic node-negativity (ypN0) in patients who received neoadjuvant chemotherapy (NAC) to develop and validate an accurate prediction nomogram. Methods: The...
8.
Fang J, Yu T, Jiang X, Lu Y, Shang X, Shen H, et al.
Open Med (Wars)
. 2024 May;
19(1):20240962.
PMID: 38770178
Aims: In cancer biology, the aberrant overexpression of eukaryotic translation initiation factor 5A2 (EIF5A2) has been correlative with an ominous prognosis, thereby underscoring its pivotal role in fostering metastatic progression....
9.
Zhang Q, Ouyang Q, Li W, Chiu J, Yan M, Lu Y, et al.
Transl Breast Cancer Res
. 2024 May;
3:31.
PMID: 38751523
Background: Trastuzumab is the recommended first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) patients in China, but therapeutic resistance to trastuzumab and other early-line...
10.
Liu S, Xiang Y, Gu Y, Chen N, Fu P, Wei Y, et al.
Int J Nurs Stud
. 2024 Feb;
152:104695.
PMID: 38301304
Background: Despite being a significant management decision in clinical or nursing practice, there is limited understanding of the preferences regarding risks, benefits, costs, and other attributes of patients with breast...